Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY 4.0Nutrients

Effects of Omega-3 Supplementation on Inflammatory Biomarkers and Ambulatory and Central Blood Pressure in Patients Treated for Hypertension and Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial

  • Carol Kotliar1,2,3
  • Rocío Martínez Vivot2
  • Cristian Beltramo1
  • Ezequiel Huguet1
  • Alfredo Lozada1,4
  • Laura Montecchiesi1
  • Leopoldo Marcon1
  • Sebastián Eduardo Obregón1,3
4 affiliations
  1. 1Santa María de la Salud Medical Center, Av. del Libertador 16131, San Isidro 1643, Buenos Aires, Argentina
  2. 2Institute for Biomedical Research, School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council, Alicia Moreau de Justo 1600, Capital Federal, Buenos Aires 1107, Argentina
  3. 3Center of Hypertension, Institute of Cardiology, Hospital Universitario Austral, Av.Perón 1500, Pilar 1629, Buenos Aires, Argentina
  4. 4Cholesterol Clinic, Hospital Universitario Austral, Av.Perón 1500, Pilar 1629, Buenos Aires, Argentina
Open at sourceDOICite

Abstract

Background: Omega-3 fatty acids exert anti-inflammatory and hemodynamic effects; however, their concurrent effects in patients receiving treatment for hypertension and dyslipidemia remain incompletely characterized. Objective: To evaluate the effects of 12 weeks of supplementation with pharmaceutical-grade omega-3 fatty acids on inflammatory biomarkers, central and brachial blood pressure including office and 24 h ambulatory measurements, and vascular function in this population. Methods: In this exploratory, randomized, double-blind, placebo-controlled pilot trial, 100 adults received omega-3 ethyl esters at a capsule dose of 2 g/day or a matching placebo for 12 weeks, in addition to stable usual pharmacological treatment. Treatment effects were estimated using linear mixed-effects models. p-values were nominal, and 95% confidence intervals were not adjusted for multiplicity. Results: Compared with placebo, omega-3 supplementation was associated with greater reductions in the neutrophil-to-lymphocyte ratio (NLR; −0.43; 95% CI, −0.73 to −0.13; p = 0.005), ferritin (−47.32 ng/mL; 95% CI, −77.55 to −17.08; p = 0.003), daytime systolic blood pressure (−6.52 mmHg; 95% CI, −10.66 to −2.39; p = 0.002), nighttime diastolic blood pressure (−5.55 mmHg; 95% CI, −9.87 to −1.22; p = 0.013), central systolic blood pressure (−6.71 mmHg; 95% CI, −12.22 to −1.20; p = 0.019), and estimated pulse wave velocity (−0.77 m/s; 95% CI, −1.19 to −0.36; p < 0.001). Conclusions: The trial identified exploratory signals involving NLR, ferritin, selected ambulatory blood-pressure measures, central systolic blood pressure, and algorithm-derived ePWV. Multiplicity, limited sample size, and incomplete outcome availability preclude confirmatory interpretation. Independent replication in larger, prospectively registered trials with clearly specified endpoints and reproducible sample-size calculations is required.

Related

  1. Fruit Smoothie Supplementation and Inflammatory Biomarkers in Individuals Receiving Opioid Agonist Therapy: A Multicenter Randomized Controlled Trial
    Lise M. Thomassen, Elaheh J. Arjmand, Karl T. Druckrey-Fiskaaen +10
    NutrientsPeer-reviewedCC BY 4.0NutritionCrossref
  2. Prevalence and Associated Factors of Hypertension–Diabetes–Dyslipidemia Clustering Among Adults — Hainan Province, China, 2023
    Juan Jiang, Tingting Ou, Ying Liu +6
    China CDC weeklyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Real-World Outcomes of Virtual Medical Nutrition Therapy in Dyslipidemia, Hypertension, or Diabetes
    R. N. Adams, D. Mozaffarian, C. Bollinger
    medRxivPreprintCC BY-NC-NDFull textNutritionmedRxiv
  4. Hypertriglyceridemic waist-to-height ratio and the triple burden of hypertension, diabetes, and dyslipidemia in adults: association and network analysis.
    Lanqiqi Wu, Jiaoyang Chen, Ting He +6
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref
  5. Optical coherence tomography angiography findings in newly diagnosed hypertension patients with 24-h ambulatory blood pressure monitoring
    Cansu Sipal Kabayel, Bengi Ece Kurtul, Alparslan Kurtul
    Taiwan Journal of OphthalmologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineDOAJ

Cite

BibTeXRIS
BibTeX
@article{kotliar2026effects,
  title = {{Effects of Omega-3 Supplementation on Inflammatory Biomarkers and Ambulatory and Central Blood Pressure in Patients Treated for Hypertension and Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial}},
  author = {Carol Kotliar and Rocío Martínez Vivot and Cristian Beltramo and Ezequiel Huguet and Alfredo Lozada and Laura Montecchiesi and Leopoldo Marcon and Sebastián Eduardo Obregón},
  journal = {Nutrients},
  year = {2026},
  month = nov,
  doi = {10.3390/nu18213717},
  url = {https://www.mdpi.com/2072-6643/18/21/3717},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Effects of Omega-3 Supplementation on Inflammatory Biomarkers and Ambulatory and Central Blood Pressure in Patients Treated for Hypertension and Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial
AU  - Carol Kotliar
AU  - Rocío Martínez Vivot
AU  - Cristian Beltramo
AU  - Ezequiel Huguet
AU  - Alfredo Lozada
AU  - Laura Montecchiesi
AU  - Leopoldo Marcon
AU  - Sebastián Eduardo Obregón
PY  - 2026
DA  - 2026/11/09
JO  - Nutrients
DO  - 10.3390/nu18213717
UR  - https://www.mdpi.com/2072-6643/18/21/3717
AB  - Background: Omega-3 fatty acids exert anti-inflammatory and hemodynamic effects; however, their concurrent effects in patients receiving treatment for hypertension and dyslipidemia remain incompletely characterized. Objective: To evaluate the effects of 12 weeks of supplementation with pharmaceutical-grade omega-3 fatty acids on inflammatory biomarkers, central and brachial blood pressure including office and 24 h ambulatory measurements, and vascular function in this population. Methods: In this exploratory, randomized, double-blind, placebo-controlled pilot trial, 100 adults received omega-3 ethyl esters at a capsule dose of 2 g/day or a matching placebo for 12 weeks, in addition to stable usual pharmacological treatment. Treatment effects were estimated using linear mixed-effects models. p-values were nominal, and 95% confidence intervals were not adjusted for multiplicity. Results: Compared with placebo, omega-3 supplementation was associated with greater reductions in the neutrophil-to-lymphocyte ratio (NLR; −0.43; 95% CI, −0.73 to −0.13; p = 0.005), ferritin (−47.32 ng/mL; 95% CI, −77.55 to −17.08; p = 0.003), daytime systolic blood pressure (−6.52 mmHg; 95% CI, −10.66 to −2.39; p = 0.002), nighttime diastolic blood pressure (−5.55 mmHg; 95% CI, −9.87 to −1.22; p = 0.013), central systolic blood pressure (−6.71 mmHg; 95% CI, −12.22 to −1.20; p = 0.019), and estimated pulse wave velocity (−0.77 m/s; 95% CI, −1.19 to −0.36; p < 0.001). Conclusions: The trial identified exploratory signals involving NLR, ferritin, selected ambulatory blood-pressure measures, central systolic blood pressure, and algorithm-derived ePWV. Multiplicity, limited sample size, and incomplete outcome availability preclude confirmatory interpretation. Independent replication in larger, prospectively registered trials with clearly specified endpoints and reproducible sample-size calculations is required.
SN  - 2072-6643
ER  -